3d bioassays to measure antibody-dependent cell-mediated cytotoxicity
OwnerXiaoqing Jia, Min Cheninventors
Life of this patent
Estimating the term…
Abstract
Provided herein are 3D bioassays to measure antibody-dependent cell-mediated cytotoxicity (ADCC). In particular, provided is a method for assessing ADCC comprising contacting an antibody or a functional antibody fragment thereof with a target cell and an effector cell expressing FcR, in a 3D cell culture under a condition allowing the interactions between those substances; and detecting the changes in the expression levels of biomarkers CXCL9, CXCL10 and CXCL11 and 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers selected from UBD, IDOL, STEAP4, JAG1, APOL4, GBP4, CD274, GBP5, CCL3 and CCL4; and assessing ADCC of the antibody based on the expression results. Also provided are the use and product relate to the method.
Claims22
A method for assessing antibody-dependent cell-mediated cytotoxicity (ADCC), wherein the method comprises:
- A) contacting (i) an antibody or a functional antibody fragment thereof;
- with (ii) a target cell;
- and (iii) an effector cell expressing FcR, in a 3D cell culture under a condition allowing the interactions between those substances;
- B) detecting the changes in the expression levels of biomarkers CXCL9, CXCL10 and CXCL11 and 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers selected from UBD, IDO1, STEAP4, JAG1, APOL4, GBP4, CD274, GBP5, CCL3 and CCL4;
- and
- C) assessing ADCC of the antibody based on the result obtained in step B).
A kit comprising agents for detecting the expression levels of CXCL9, CXCL10 and CXCL11, and 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers selected from UBD, IDO1, STEAP4, JAG1, APOL4, GBP4, CD274, GBP5, CCL3 and CCL4.
A system for assessing antibody-dependent cell-mediated cytotoxicity (ADCC), comprising:
- a) means for contacting (i) an antibody or a functional antibody fragment thereof;
- with (ii) a target cell;
- and (iii) an effector cell expressing FcR, in a 3D cell culture under a condition allowing the interactions between those substances;
- and
- b) means for determining the expression levels of biomarkers CXCL9, CXCL10 and CXCL11 and 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers selected from UBD, IDO1, STEAP4, JAG1, APOL4, GBP4, CD274, GBP5, CCL3 and CCL4.
Dependencies are inferred from the claim text.